Sunesis Pharmaceuticals Inc (SNSS)

0.26 -0.00  -1.85% NASDAQ Jul 16, 08:27 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
08/07/2020 16:30 EDT Misc Sunesis Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2020
08/07/2020 Earnings Sunesis Pharmaceuticals Inc Second Quarter Earnings in 2020 Release
06/16/2020 Misc Sunesis Pharmaceuticals Inc Annual General Meeting for 2019
05/07/2020 16:30 EDT Misc Sunesis Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020
05/07/2020 Earnings Sunesis Pharmaceuticals Inc First Quarter Earnings Result for 2020
03/10/2020 16:30 EDT Misc Sunesis Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019
03/10/2020 Earnings Sunesis Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
03/10/2020 Misc Sunesis Pharmaceuticals Inc Annual Report for 2019
11/12/2019 16:30 EST Misc Sunesis Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
11/12/2019 Earnings Sunesis Pharmaceuticals Inc Third Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.sunesis.com
  • Investor Relations URL: http://ir.sunesis.com/phoenix.zhtml?c=194116&p=irol-IRHome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Aug. 07, 2020
  • Last Earnings Release: May. 07, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.